Center for Child and Community Health Research, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and.
J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):593-600. doi: 10.1097/QAI.0000000000002506.
HIV pre-exposure prophylaxis (PrEP) retention, defined as quarterly clinical evaluation, is critical to reducing HIV incidence. Our objectives were to determine: (1) visit- and individual-level PrEP retention patterns; (2) and individual-level characteristics associated with low-level PrEP retention 12 months after initiation among PrEP users in Baltimore City, Maryland.
Information was abstracted from medical records among individuals initiating PrEP between October 1, 2015 and February 28, 2018. Visit-level PrEP retention was defined as evidence of PrEP use, documented PrEP prescription, or current PrEP use at each quarterly follow-up visit. Low-level PrEP retention was defined as <3/4 quarters with documented PrEP use. Multilevel mixed effects Poisson regression was used to determine characteristics associated with low-level PrEP retention.
Among 412 individuals initiating PrEP and followed for 12 months, the majority was: cis-gender male (83.7%, n = 345), non-Hispanic Black (56.3%, n = 232) and gay, bisexual, or other man who has sex with men (74.0%, n = 305). By quarterly visits, PrEP retention was: 3-month: 69.4% (n = 286); 6-month: 51.9% (n = 214); 9-month: 44.5% (n = 183); and 12-month: 41.1% (n = 169). Three-fifths (58.5%, n = 241) had low-level PrEP retention. Cis-gender females (vs. cis-gender males) (adjusted relative risk: 1.36, 95% confidence interval: 1.04 to 1.77) were more likely to have low-level PrEP retention.
Our observed PrEP retention rates are lower than what may be needed to reduce HIV incidence. Future research should examine individual- and clinic-level barriers and facilitators to PrEP retention programs by key population to inform interventions for PrEP retention.
艾滋病毒暴露前预防(PrEP)保留率,定义为每季度进行临床评估,对降低艾滋病毒发病率至关重要。我们的目标是确定:(1)就诊和个体层面的 PrEP 保留模式;(2)以及在马里兰州巴尔的摩市开始使用 PrEP 后 12 个月时与低水平 PrEP 保留相关的个体特征。
从 2015 年 10 月 1 日至 2018 年 2 月 28 日期间开始接受 PrEP 的个人的医疗记录中提取信息。就诊层面的 PrEP 保留率定义为每季度随访时均有证据表明使用了 PrEP、有记录的 PrEP 处方或当前正在使用 PrEP。低水平 PrEP 保留率定义为 <3/4 个季度有记录的 PrEP 使用情况。使用多级混合效应泊松回归来确定与低水平 PrEP 保留相关的特征。
在 412 名开始接受 PrEP 并随访 12 个月的个体中,大多数是:顺性别男性(83.7%,n=345)、非西班牙裔黑人(56.3%,n=232)和男同性恋、双性恋或其他与男性发生性关系的男性(74.0%,n=305)。按季度就诊,PrEP 保留率为:3 个月:69.4%(n=286);6 个月:51.9%(n=214);9 个月:44.5%(n=183);12 个月:41.1%(n=169)。五分之三(58.5%,n=241)的人 PrEP 保留水平较低。顺性别女性(与顺性别男性相比)(调整后的相对风险:1.36,95%置信区间:1.04 至 1.77)更有可能保留低水平的 PrEP。
我们观察到的 PrEP 保留率低于降低 HIV 发病率所需的水平。未来的研究应通过关键人群检查 PrEP 保留计划的个体和诊所层面的障碍和促进因素,为 PrEP 保留干预措施提供信息。